Novavax Breakthrough: Positive Results in COVID and Influenza Vaccine Trials

After the dramatic decline reported by the Novavax company of 88% due to the decrease in sales of vaccines against covid-19, the company had a breakthrough this week in vaccines and innovation.

After the second trial of a vaccine that aims to combine the drug against Covid-19 and influenza, the results have been positive demonstrating robust immune responses.

Their criteria for evaluating the vaccine examined the safety of various formulations of the CIC vaccine candidate and the quadrivalent influenza vaccine candidate compared to Fluad and Fluozone High-Dose Quadrivalent (Fluzone HD). On the other hand, vaccine was evaluated Covid which is intended for adults from 50 to 80 years old.

The tests showed that the reactogenicity profile remained constant as the dose of adjuvant or antigen was increased. It was also noted that there were no adverse effects that raised any alarm, no potentially immune-mediated medical conditions were detected either.

“The reactogenicity results support our previous observations that this technology is well suited for combination vaccines because large amounts of antigen can be incorporated without affecting tolerability,” said Novavax President of Research and Development Filip Dubovsky. He also added that “the immune responses we observed were robust, and the data we have shared today significantly increases the likelihood of Phase 3 success.”

This new vaccine reached immunoglobulin G (IgG) and neutralization levels similar to those of the covid vaccine launched by Novavax. Likewise, several of the combination formulations achieved an optimistic response against Sars-CoV-2 and the four homologous influenza strains that can be compared to other references.

It should also be noted that this Covid and influenza candidate vaccine achieved statistically significant anti-S IgG and neutralization responses. According to the results, this reflects a 30% higher response to the prototype Covid vaccine produced by Novavax, provided safety against safety and reactogenicity standards comparable to the currently licensed dose level of Nuvaxovid.

“Today’s positive data is encouraging and further validate the value of our technology platform and its potential to improve global public health,” said Novavax President and CEO John C. Jacobs.

“This is an important milestone on our journey to create additional value and diversify our vaccine portfolio,” he added.

This new vaccine could be timely for manage the crisis that the company is going through due to the end of the crisis of the Covid-19which has led them to cut 25% of their employees and generate other strategies to stay active in the market.

“Reducing our workforce has been a difficult decision, but we believe it was necessary to better align our infrastructure and scale to the endemic COVID opportunity,” CEO John Jacobs stated in the statement.